Author

R.-M. Ferraiuolo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B.-A. Fifield· 2 shared L. A. Porter· 2 shared A. Basilious· 1 shared C. Gramisteanu· 1 shared C. Hamm· 1 shared C. Pecoraro· 1 shared E. Mailloux· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B.-A. Fifield

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Cyclin-Like Protein Spy1 Mediates Tumourigenic Potential of Triple Negative Breast Cancer

B.-A. Fifield, C. Pecoraro, A. Basilious, C. Gramisteanu, E. Mailloux, R.-M. Ferraiuolo, L. A. Porter

This study shows that knocking out Spy1 reduces proliferation, metastasis, and stemness in triple negative breast cancer cells and enhances chemotherapy response.

bioRxiv · Mar 11, 2024 · PreprintCancer Biology

THE STABILIZATAION OF C-MYC BY THE NOVEL CELL CYCLE REGULATOR, SPY1, DECREASES EFFICACY OF BREAST CANCER TREATMENTS

R.-M. Ferraiuolo, B.-A. Fifield, C. Hamm, L. A. Porter

This study shows that Spy1 stabilizes c-Myc, reducing breast cancer treatment efficacy, and that targeting Spy1 can enhance chemotherapy response in TNBC.

bioRxiv · Mar 11, 2022 · PreprintCancer Biology